Klotho Neurosciences CFO Awarded 200K Shares as Employment Compensation

Rhea-AI Filing Summary

Klotho Neurosciences (KLTO) insider stock grant: Chief Financial Officer Jeffrey Brian LeBlanc received 200,000 shares of common stock on 08/25/2025 under his employment agreement, increasing his direct beneficial ownership to 920,342 shares. The Form 4 indicates the shares were acquired (not purchased) as compensation per the employment arrangement. No derivative transactions, dispositions, or additional terms (such as vesting or price) are disclosed in this filing.

Positive

• CFO received equity compensation aligning management incentives with shareholders
• Clear disclosure of the number of shares acquired and resulting direct ownership

Negative

• No vesting or price information provided, limiting assessment of dilution timing and compensation expense
• Filing lacks detail on any conditions or restrictions attached to the awarded shares

Insights

Corporate Governance Expert

TL;DR: CFO received a sizeable equity grant, raising direct ownership to 920,342 shares; disclosed as compensation under his employment agreement.

The disclosure shows a non‑derivative grant of 200,000 common shares to the company's Chief Financial Officer as compensation. For governance readers, this is a routine equity award to align management incentives with shareholders. The filing does not disclose vesting conditions, fair value, exercise price, or any hedging arrangements, limiting assessment of dilution timing and expense recognition. Reporting is limited to the mechanics of the transfer and resulting ownership stake.

Securities Analyst

TL;DR: A direct stock acquisition increases the CFO's stake; the transaction is compensatory rather than market purchase.

From a securities perspective, the reported transaction is an A‑code acquisition of 200,000 shares, increasing direct beneficial ownership to 920,342 shares. Because the filing lacks price and vesting details, one cannot quantify immediate dilution, expense impact, or potential future share availability. The transaction itself is material to insider ownership metrics but contains limited financial detail in this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeBlanc Jeff

(Last) (First) (Middle)

1300 SOUTH BOULEVARD SUITE D

(Street)

CHARLOTTE NC 28203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Klotho Neurosciences, Inc. [ KLTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		A		200,000	A	(1)	920,342	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person received the shares pursuant to his employment agreement with the Issuer.

Remarks:

	Jeffrey Brian LeBlanc	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Jeff LeBlanc report on the Form 4 for Klotho Neurosciences (KLTO)?

The Form 4 reports an acquisition of 200,000 common shares on 08/25/2025 by CFO Jeffrey Brian LeBlanc.

How many Klotho Neurosciences shares does the reporting person own after the transaction?

After the reported transaction, the filing shows 920,342 shares beneficially owned directly by the reporting person.

Was the share acquisition a purchase or compensation?

The filing states the shares were received pursuant to the reporting person’s employment agreement, indicating compensation rather than a market purchase.

Does the Form 4 disclose vesting terms or price for the awarded shares?

No. The filing does not disclose vesting, price, fair value, or restrictions on the awarded shares.

Are there any derivative securities reported by the reporting person?

No. Table II for derivative securities contains no reported transactions in this filing.